2008 FDA trends

It's never too early to identify trends, and what better place to look than the FDA? The environment at the world's premier regulatory agency can have a significant impact the U.S. as well as the world markets, so it's always wise to keep an eye on happenings at the FDA. In that vein, here's an early look at four FDA trends we've identified so far this year. Special report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.